Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
NCT ID: NCT01369784
Last Updated: 2016-04-18
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
158 participants
OBSERVATIONAL
2009-02-28
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme
NCT06734078
Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen
NCT01478269
Study of Prognostic Factors in Adult Lymphoblastic Lymphoma
NCT03571997
Refractory Diffuse Large B-cell Lymphoma
NCT03664336
Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT05338892
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
refractory/relapsed LDCBG
patients with refractory/relapsed diffuse large B-cell lymphoma
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with refractory/relapsed diffuse large B-cell lymphoma after first line treatment with rituximab, with or without transplantation. Patients must have finished a rescue treatment including rituximab
* Ability to understand and willingness to sign a written informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carlos Panizo, PhD
Role: STUDY_CHAIR
Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital de Elda
Elda, Alicante, Spain
H. U. Germans Trias i Pujol
Badalona, Barcelona, Spain
Hospital Clinic i Provincial
Barcelona, Barcelona, Spain
Hospital del Mar
Barcelona, Barcelona, Spain
Hospital Vall D'Hebrón
Barcelona, Barcelona, Spain
Hospital General de Granollers
Granollers, Barcelona, Spain
ICO-DYR
L'Hospitalet de Llobregat, Barcelona, Spain
Althaia
Manresa, Barcelona, Spain
Hospital de Mataró
Mataró, Barcelona, Spain
Hospital Parc Taulí
Sabadell, Barcelona, Spain
H. Sierrallana
Torrelavega, Cantabria, Spain
Hospital General del SAS de Jerez
Jerez de la Frontera, Cádiz, Spain
Institut Catalá d'Oncologia de Girona
Girona, Gerona, Spain
H.U. Virgen de las Nieves
Granada, Granada, Spain
Hospital Galdakao
San Sebastián, Guipuzcoa, Spain
Complejo Hospitalario de Jaén
Jaén, Jaén, Spain
C.H.U. A Coruña
A Coruña, La Coruña, Spain
H. Clínico U. Santiago de Compostela
Santiago de Compostela, La Coruña, Spain
Hospital San Pedro
Logroño, La Rioja, Spain
Hospital de León
León, León, Spain
Hospital Xeral
Lugo, Lugo, Spain
Hospital Universitario Arnau de Vilanova
Lleida, Lérida, Spain
H.U. Fundación Alcorcón
Alcorcón, Madrid, Spain
H.U.de Getafe
Getafe, Madrid, Spain
H. Severo Ochoa
Leganés, Madrid, Spain
H. Ramón y Cajal
Madrid, Madrid, Spain
H. U. La Princesa
Madrid, Madrid, Spain
H.G.U. Gregorio Marañón
Madrid, Madrid, Spain
H.U. La Paz
Madrid, Madrid, Spain
Hospital 12 de Octubre
Madrid, Madrid, Spain
MD Anderson
Madrid, Madrid, Spain
Hospital Son Llatzer
Mallorca, Mallorca, Spain
H.U. Virgen de la Arrixaca
Murcia, Murcia, Spain
Hospital Morales Messeguer
Murcia, Murcia, Spain
Hospital Costa del Sol
Marbella, Málaga, Spain
H. Carlos Haya
Málaga, Málaga, Spain
Clínica Universitaria de Navarra
Pamplona, Navarre, Spain
Hospital de Navarra
Pamplona, Navarre, Spain
Complexo Hospitalario de Ourense
Ourense, Orense, Spain
Hospital Universitario Son Dureta
Palma de Mallorca, Palma de Mallorca, Spain
Hospital de Cabueñes
Gijón, Principality of Asturias, Spain
H. U. Central de Asturias
Oviedo, Principality of Asturias, Spain
H. Universitario de Salamanca
Salamanca, Salamanca, Spain
H. General de Segovia
Segovia, Segovia, Spain
H.U. Nuestra Señora de Valme
Seville, Sevilla, Spain
H. Universitario de Canarias
San Cristóbal de La Laguna, Tenerife, Spain
H. Nuestra Señora del Prado
Talavera de la Reina, Toledo, Spain
H. Arnau de Vilanova
Valencia, Valencia, Spain
H. Clínico de Valencia
Valencia, Valencia, Spain
H. Dr. Peset
Valencia, Valencia, Spain
H. Río Hortega
Valladolid, Valladolid, Spain
Hospital Clínico Universitario Valladolid
Valladolid, Valladolid, Spain
H. Basurto
Bilbao, Vizcaya, Spain
H. Virgen de La Concha
Zamora, Zamora, Spain
H. Txagorritxu
Vitoria-Gasteiz, Álava, Spain
H. Nuestra Señora de Sonsoles
Ávila, Ávila, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRO-R-IPI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.